21,075 Shares in Horizon Therapeutics PLC (NASDAQ:HZNP) Acquired by CIBC World Markets Inc.

CIBC World Markets Inc. bought a new stake in shares of Horizon Therapeutics PLC (NASDAQ:HZNP) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 21,075 shares of the biopharmaceutical company’s stock, valued at approximately $557,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Norges Bank purchased a new position in Horizon Therapeutics during the 4th quarter valued at $46,493,000. FMR LLC lifted its holdings in shares of Horizon Therapeutics by 361.8% in the 4th quarter. FMR LLC now owns 1,963,146 shares of the biopharmaceutical company’s stock worth $38,360,000 after buying an additional 1,538,056 shares during the period. D. E. Shaw & Co. Inc. raised its position in shares of Horizon Therapeutics by 63.8% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 3,369,508 shares of the biopharmaceutical company’s stock worth $65,840,000 after acquiring an additional 1,312,142 shares in the last quarter. Victory Capital Management Inc. bought a new position in shares of Horizon Therapeutics in the 1st quarter worth $27,663,000. Finally, Jennison Associates LLC raised its position in shares of Horizon Therapeutics by 57.1% in the 4th quarter. Jennison Associates LLC now owns 2,220,567 shares of the biopharmaceutical company’s stock worth $43,390,000 after acquiring an additional 807,401 shares in the last quarter. 87.79% of the stock is currently owned by hedge funds and other institutional investors.

In related news, insider Jeff Kent sold 3,620 shares of the stock in a transaction on Wednesday, June 5th. The stock was sold at an average price of $24.64, for a total value of $89,196.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 4.10% of the stock is currently owned by corporate insiders.

Several research analysts recently issued reports on the company. Morgan Stanley raised Horizon Therapeutics from an “equal weight” rating to an “overweight” rating and set a $32.00 target price on the stock in a research report on Friday, March 8th. BidaskClub raised Horizon Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, May 10th. TheStreet lowered Horizon Therapeutics from a “b-” rating to a “c+” rating in a report on Monday, June 10th. Mizuho set a $27.00 target price on Horizon Therapeutics and gave the stock a “hold” rating in a research note on Wednesday, May 8th. Finally, BMO Capital Markets upped their target price on Horizon Therapeutics to $29.00 and gave the stock a “market perform” rating in a research note on Thursday, April 4th. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $30.83.

HZNP stock traded up $0.89 during trading on Monday, hitting $24.95. The company had a trading volume of 1,999,344 shares, compared to its average volume of 1,919,197. The stock has a market cap of $4.55 billion and a price-to-earnings ratio of 13.63. Horizon Therapeutics PLC has a 1-year low of $16.11 and a 1-year high of $29.44. The company has a 50-day simple moving average of $24.63. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.68 and a current ratio of 1.74.

Horizon Therapeutics (NASDAQ:HZNP) last announced its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported $0.30 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.10 by $0.20. Horizon Therapeutics had a return on equity of 33.57% and a net margin of 3.79%. The business had revenue of $280.00 million for the quarter, compared to analyst estimates of $238.35 million. During the same quarter in the previous year, the company earned $0.03 EPS. The company’s quarterly revenue was up 25.0% on a year-over-year basis. As a group, research analysts forecast that Horizon Therapeutics PLC will post 1.62 EPS for the current year.

About Horizon Therapeutics

Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.

Read More: Calculating net profit and net profit margin ratio

Institutional Ownership by Quarter for Horizon Therapeutics (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.